In some patients with HS the use of TNF antagonists, like adalimumab, increases up to a two-fold the risk of developing SCC and may shorten the time to the development of NMSC, particularly in psoriatic patients [60,76,82,83]. This evidence concerns the gene TNF and histiocytic sarcoma.